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Abstract
Background
High blood pressure is a leading risk factor for death and disability in sub-Saharan Africa
(SSA). We evaluated the costs and cost-effectiveness of hypertension care provided within
the Kwara State Health Insurance (KSHI) program in rural Nigeria.
Methods
AMarkov model was developed to assess the costs and cost-effectiveness of population-
level hypertension screening and subsequent antihypertensive treatment for the population
at-risk of cardiovascular disease (CVD) within the KSHI program. The primary outcome was
the incremental cost per disability-adjusted life year (DALY) averted in the KSHI scenario
compared to no access to hypertension care. We used setting-specific and empirically-col-
lected data to inform the model. We defined two strategies to assess eligibility for antihyper-
tensive treatment based on 1) presence of hypertension grade 1 and 10-year CVD risk of
>20%, or grade 2 hypertension irrespective of 10-year CVD risk (hypertension and risk
based strategy) and 2) presence of hypertension in combination with a CVD risk of >20%
(risk based strategy). We generated 95% confidence intervals around the primary outcome
through probabilistic sensitivity analysis. We conducted one-way sensitivity analyses
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Results
Screening and treatment for hypertension was potentially cost-effective but the results were
sensitive to changes in underlying assumptions with a wide range of uncertainty. The incre-
mental cost-effectiveness ratio for the first and second strategy respectively ranged from
US$ 1,406 to US$ 7,815 and US$ 732 to US$ 2,959 per DALY averted, depending on the
assumptions on risk reduction after treatment and compared to no access to antihyperten-
sive treatment.
Conclusions
Hypertension care within a subsidized private health insurance program may be cost-effec-
tive in rural Nigeria and public-private partnerships such as the KSHI programmay provide
opportunities to finance CVD prevention care in SSA.
Introduction
Raised blood pressure is the leading risk factor for disease burden and mortality worldwide,
mainly due to associated cardiovascular diseases (CVD).[1,2] Nearly 80% of CVD-related mor-
tality occurs in low- and middle-income countries (LMICs).[3,4] People in LMICs die from
CVD at a younger age compared to people in high income countries, often in their most pro-
ductive years. CVD in LMICs have a large economic impact, both at household and macro-
economic level, due to catastrophic healthcare expenditures and through loss of income and
labour productivity.[3,4]
The prevalence of hypertension and its complications is increasing rapidly in sub-Saharan
Africa (SSA) with an age-standardized hypertension prevalence of 19.1% in 1990 compared to
25.9% in 2010.[1,5,6] Adequate treatment of hypertension greatly reduces the risk of CVD.[7]
However, treatment coverage of antihypertensive medication is low due to limited awareness,
accessibility and affordability of quality treatment for hypertension in settings with overbur-
dened health systems.[6,8–11] There is an urgent need to develop and evaluate the costs and
effects of innovative service delivery models for the management of hypertension that guaran-
tee access to high quality care for patients.
The Kwara State Health Insurance (KSHI) program is an initiative of the Kwara State Gov-
ernment[12], Hygeia Community Health Care (HCHC)[13], the Health Insurance Fund[14]
and PharmAccess Foundation[15] to improve access to affordable and quality healthcare for
low income population in Kwara State, rural Nigeria. The insurance program provides cover-
age for primary and limited secondary care, including antihypertensive treatment. In addition,
the program aims to improve the quality of care in the participating healthcare facilities by
facilitating the upgrade of their infrastructure, training of staff in guideline-based care, and
management support. Individual enrolment in the program is voluntary and participants pay
about 12% of the premium. At the time of the study, the participant part of the premium was
approximately US$ 2 per year, currently the participants pay approximately US$ 3 per year.
The remaining part of the premium is subsidized, mainly by the Kwara State Government (see
section B in S1 File for more information).
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Previous studies have shown hypertension treatment to be a cost-effective intervention in
high risk individuals in modelling studies from SSA. [16–21] We previously showed that
hypertension management through the KSHI program was effective in reducing blood pressure
in a cohort of people with hypertension[22,23] and evaluated costs of hypertension care from a
healthcare perspective.[24] In this paper, we aim to evaluate the costs and cost-effectiveness of
hypertension management through the KSHI program at scale, for the population at risk of
CVD using empirical data from our previous studies and program monitoring databases.
To the best of our knowledge, this study is the first economic evaluation of hypertension
treatment in SSA to use empirically collected data on population risk distributions, cost of care,
treatment coverage and blood pressure reduction after treatment. In addition, it is the first
study to incorporate the costs of setting up and managing a service delivery model that pro-
vides access to care for patients. Furthermore, we have tested a large set of assumptions across
key model parameters, some of which have not yet been addressed in previous cost-effective-
ness studies of hypertension treatment in SSA.[16,18,19,21]
Materials and Methods
We developed a Markov model to assess the costs and cost-effectiveness of population-level
hypertension screening and subsequent antihypertensive treatment in the context of a health
insurance program, from the healthcare provider perspective. We compared this intervention
to a reference scenario where the insurance program is not operational and people do not have
access to screening or treatment for hypertension. The choice for this reference scenario was
based on the observation that insurance coverage and antihypertensive treatment coverage in
the population was 0% and 4.6% respectively before the program was rolled-out.[22,23] Infor-
mation regarding the quality of the antihypertensive treatment or the continuity of the treat-
ment was unavailable. We simulated a cohort of 10,000 individuals aged 30–79 years with no
previous CVD for ten years. The primary outcome was the incremental cost per disability-
adjusted life year (DALY) averted.
2.1 Model
We characterized the individuals into 192 unique CVD risk profiles based on sex, age, blood
pressure, the presence of diabetes mellitus, smoking status, and total cholesterol. The distribu-
tion of risk factors in the population were sourced from population-based household surveys
undertaken as part of the overall evaluation of the KSHI program (Table 1). These surveys
were conducted in rural Kwara State. In the surveys, demographic, socioeconomic and medical
information including measurements of blood pressure, and cholesterol were collected. Ethical
clearance for the surveys conducted in Kwara was obtained from the ethical review committee
of the University of Ilorin Teaching Hospital (04/08/2008, UITH/CAT189/11/782). Informed
consent was obtained from all participants by signature or by fingerprint, as approved by the
ethical review committee. The methods used for these surveys and a description of the study
setting are described briefly in the supplement (S1 File sections A and B) and in more detail
elsewhere. [8,22,23]
In our model, every year individuals experience a risk of having a stroke or a coronary heart
disease (CHD) event; these events could be either fatal (defined as death within one year of the
event) or non-fatal (Fig 1).
The probabilities of having a stroke or a CHD event (including myocardial infarction (MI)
and angina pectoris (AP)) were based on the Framingham ten-year risk equations for stroke
and CHD [25,26] and converted to one-year probabilities for every one-year cycle in the ten-
year period. The proportions of fatal and non-fatal stroke and CHD events as well as the
Hypertension Screening and Treatment in Nigeria
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Table 1. Input parameters for cost-effectiveness analyses.
Population and risk factor
distributions
Proportion (SE) Average (SE) Distribution Source #
Age categories
30–44 years old 0.37 (0.01) 35.8 (0.15) Beta Kwara HH survey
45–59 years old 0.34 (0.01) 50.1 (0.15) Beta Kwara HH survey
60–69 years old 0.19 (0.01) 62.5 (0.14) Beta Kwara HH survey
70–79 years old 0.11 (0.01) 71.8 (0.17) Beta Kwara HH survey
Gender, male 0.45 (0.01) - Beta Kwara HH survey
Hypertension severity^
No hypertension 0.77 (0.01) 114.0 (0.30) Beta Kwara HH survey
Hypertension, stage 1 0.13 (0.01) 142.66 (0.56) Beta Kwara HH survey
Hypertension, stage 2 0.11 (0.01) 173.49 (1.36) Beta Kwara HH survey
Total Cholesterol
TC > 5 mmol/L 0.08 (0.01) 5.49 (0.05) Beta Kwara HH survey
TC < = 5 mmol/L 0.92 (0.01) 3.66 (0.02) Beta Kwara HH survey
High Density Lipoprotein
Cholesterol
TC > 5 mmol/L* 0.08 (0.01) 1.36 (0.09) Beta Kwara HH survey
TC < = 5 mmol/L* 0.92 (0.01) 1.08 (0.02) Beta Kwara HH survey
Current daily smoking 0.12 (0.01) N.A. Beta Kwara HH survey
Diabetes 0.04 (0.01) N.A. Beta Kwara HH survey
Probabilities and
outcomes in model
Stroke event Base Case Range Distribution Source #
Probability of stroke event Framingham risk score per risk proﬁle per year [26]
Probability of stroke to be
fatal within one year
0.53 0.50–0.57 Triangular [30–42]
Survival time if stroke fatal
within one year
82.0 days 77.6–89.6 days Triangular [30–42]
Survival time if stroke non-
fatal within one year
Age- and gender-speciﬁc, adapted to Nigeria [43,44]
CHD event Base Case Range Distribution Source #
Probability of CHD event Framingham risk score per risk proﬁle per year [25]
Probability of CHD to be
fatal within one year
0.30 0.26–0.33 Triangular [16,45,46]
Survival time if CHD fatal
within one year
49.3 days 44.3–61.3 days Triangular [16,45,46]
Survival time if CHD non-
fatal within one year
Age- and gender-speciﬁc, adapted to Nigeria [44,47]
Other death Distribution Source #
Probability of non-CVD
mortality per year
Age- and gender-speciﬁc table in supplement [44]
Hypertension treatment Base Case Range Distribution Source #
Coverage in KSHI program 29% - - Kwara HH survey
SBP decrease–individuals
on antihypertensive
treatment (mmHg)
-20 (-31.6–-8.4) Triangular Kwara HH survey
SBP decrease–screened
hypertensive individuals, not
on antihypertensive
treatment (mmHg)
-2.4 (-6.0–0) Triangular Kwara HH survey
(Continued)
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Table 1. (Continued)
Relative risk reduction
(RRR) per 10 mmHg SBP
decrease
Base Case Range Distribution Source #
RRR Stroke–based on
Lawes 30–44 years old
2.38 2.13–2.63 Triangular [7]
RRR Stroke–based on
Lawes 45–59 years old
2 1.92–2.04 Triangular [7]
RRR Stroke–based on
Lawes 60–69 years old
1.56 1.52–1.61 Triangular [7]
RRR Stroke–based on
Lawes 70–79 years old
1.37 1.32–1.43 Triangular [7]
RRR CHD–based on Lawes
30–44 years old
1.92 1.54–2.38 Triangular [7]
RRR CHD–based on Lawes
45–59 years old
1.67 1.56–1.75 Triangular [7]
RRR CHD–based on Lawes
60–69 years old
1.33 1.27–1.39 Triangular [7]
RRR CHD–based on Lawes
70–79 years old
1.25 1.191.32 Triangular [7]
RRR Stroke–based on
Rapsomaniki
1.16 1.14–1.18 Triangular Calculated from[48]
RRR CHD–based on
Rapsomaniki
1.16 1.15–1.18 Triangular Calculated from[48]
Cost parameters (2012 US
$)
Base Case Range Distribution Source #
Cost of hypertension care
per patient per year
112 101–126 Triangular Adapted from [24]
Cost of screening per
person screened
5 4–6 Triangular [49]
Above-service delivery
costs of insurance program
management per patient per
year
24 - Triangular KSHI program management
Cost of acute care after a
stroke per patient
380 242–1,556 Triangular Base Case: UITH data, [24]
Range: [16,17,19,35,50–57]
Cost of follow up care after
a stroke per patient per year
240 206–275 Triangular [24]
Cost of acute care after
CHD event per patient
181 115–1,180 Triangular Base Case: UITH data, [24]
Range: [16,17,19]
Cost of follow up care after
CHD event per patient per
year
278 235–320 Triangular [24]
DALY assumptions
Base Case Range Distribution
Disability weight during
survival period after a fatal
stroke (death during ﬁrst
year)
0.553 0.363–0.738 Triangular Adapted from [27]
Disability weight during
survival after a non-fatal
stroke
0.256 0.021–0.553 Triangular Adapted from [27]
(Continued)
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average number of days of survival after CVD events that led to death within the first year after
the event were based on figures from the literature (Table 1, and Table D, Table E and section
E in S1 File). For non-fatal CVD events, we did not model repeat events but assigned an aver-
age survival time according to age and gender, based on figures from the literature (Table 1,
and Table D, Table E and section G in S1 File). Finally, individuals could also die from non-
CVD related causes. Non-CVD mortality was sourced from the 2010 Global Burden of Disease
study (Table 1, and Table A and section E in S1 File).[27]
2.2 Intervention
The intervention modeled is population-level hypertension screening and subsequent antihy-
pertensive treatment for high CVD risk individuals in the context of the KSHI program. We
defined two eligibility strategies for treatment. The first was a CVD risk and hypertension-
Table 1. (Continued)
Disability weight during
survival period after a fatal
CHD event (death during
ﬁrst year)
0.180 0.135–0.250 Triangular Adapted from [27]
Disability weight during
survival after a non-fatal
CHD event
0.09 0.022–0.234 Triangular Adapted from [27]
Disability weight while on
antihypertensive treatment
0.031 0.017–0.05 Triangular [27]
# Details on assumptions made and sources used can be found in the supplemental material.
^ No hypertension: SBP < 140 AND DBP < 90; Hypertension grade 1: SBP between 140–159 mmHg and/or DBP between 90–99 mmHg; Hypertension
grade 2: SBP of at least 160 mmHg and/or DBP of at least 100 mmHg.
* HDL was not taken as a separate variable for deﬁning risk proﬁles. HDL average was calculated for high and low TC groups.
Abbreviations: SE: Standard error; Kwara HH survey: Kwara household survey; TC: Total cholesterol; CHD: Coronary heart disease; CVD: Cardiovascular
disease; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; RRR: Relative risk reduction; KSHI: Kwara State Health Insurance; UITH:
University of Ilorin Teaching Hospital; DALY: Disability adjusted life year.
doi:10.1371/journal.pone.0157925.t001
Fig 1. Structure of the Markovmodel.
doi:10.1371/journal.pone.0157925.g001
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based strategy, where all individuals with hypertension stage 1 (systolic blood pressure between
140–159 mmHg and/or diastolic blood pressure between 90–99 mmHg)[28] combined with a
ten-year CVD risk greater than 20% as well as all individuals with hypertension stage 2 (systolic
blood pressure of at least 160 mmHg and/or diastolic blood pressure of at least 100 mmHg)
[28], regardless of their ten-year CVD risk, were eligible for hypertensive treatment.[29] These
groups are eligible for treatment according to the guidelines used in the KSHI program. The
second strategy was CVD risk based, where all hypertensive individuals with a ten-year CVD
risk greater than 20% were eligible for treatment. This approach is comparable to strategies
tested in previous cost-effectiveness studies.[16,18,19,21] We will refer to the two strategies as
the risk and hypertension based strategy and risk based strategy, respectively.
We assumed that the intervention reduced the probability of having a CVD event. Mortality
and morbidity after a CVD event were assumed to be equal in the KSHI scenario and the refer-
ence scenario (Table 1). Finally, the coverage of the intervention was assumed to be the same as
the observed antihypertensive treatment coverage in a population living in an area with access
to the KSHI program for four years. As the observed treatment coverage was four years after
access to antihypertensive care became available, this estimate includes attrition to the program
over this timeframe (Table 1, and section F, S1 File).
2.3 Costs
We considered: 1) costs of delivering hypertension care within the context of the KSHI pro-
gram, and 2) costs of CVD events (including acute care and follow-up care). The costs of deliv-
ering hypertension care were assigned only to the intervention scenario while the costs of CVD
events were assigned to events in both the intervention and the reference scenario. The costs of
delivering hypertension care included population-level screening costs, service delivery for
individual hypertension treatment and insurance program costs associated with the local oper-
ations of HCHC and program management at PharmAccess level, that we will refer to as
above-service delivery costs. The cost of population-level screening was derived fromWHO
estimates.[49] Service delivery cost for hypertension care was sourced from a costing study in
the Ogo Oluwa Hospital, a private hospital participating in the KSHI program.[24] These costs
included both direct costs for consultation, tests and drugs as well as indirect building and
overhead costs. We included costs of antihypertensive drugs and acetyl salicylic acid (aspirin)
based on observed utilization in Ogo Oluwa Hospital. An overview of components can be
found in Table F and section H in S1 File. More details on the approach and methodology of
the costing study can be found in the original publication.[24] Above-service delivery costs
were added as a mark-up to all individuals on antihypertensive treatment (Table 1). The calcu-
lation of the above-service delivery costs was based on realized and projected expenses and is
explained in detail in S1 File, Table H and section H.
Using an ingredients approach, we estimated acute care costs for stroke based on guidelines
(from LMIC for stroke[58–60] and in absence of LMIC guidelines from HIC for CHD[61,62])
as well as discussion with local specialists from the University of Ilorin Teaching Hospital
(UITH; a tertiary hospital in the program area which is one of the referral hospitals for patients
in the KSHI program) to determine what was feasible and available in the setting of our study.
Acute care costs included in-hospital stay, tests, and drugs. Highly specialized clinical interven-
tions were excluded. Data from the costing study as well as additional data from UITH on utili-
zation and costs were used (Table 1, and Table I and section H, S1 File).
We validated acute care costs with figures fromWHO-CHOICE, National Health Interview
Survey (NHIS) and literature from SSA, excluding data from South Africa where the standard
of care is higher compared to the rest of SSA.[16,17,19,35,50–57] Costs for follow-up care after
Hypertension Screening and Treatment in Nigeria
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CVD events were assumed to be equal to antihypertensive treatment costs with the addition of
a number of drugs, depending on the event (Table 1, and Table J and section H, S1 File). All
prices were collected in local currency and are presented in 2012 US$ using the mean exchange
rate of the study period (1 US$ = 154.4 NGN). Cost estimates derived from other studies were
adjusted for inflation using standard methods.[63]
2.4 Analysis
The intervention effect was attributed to two components: 1) screening for hypertension com-
bined with lifestyle advice for individuals with high blood pressure, and 2) antihypertensive
drug treatment. The magnitude of the effect was based on the results of an impact study that
we conducted in the program area where people were screened for hypertension, offered insur-
ance and access to hypertension treatment.[23] We applied blood pressure reductions as
observed for 1) individuals who were screened, told to have hypertension and given informa-
tion about lifestyle measures but who were not on pharmacological treatment during the four
year follow-up survey that was part of the impact study; and 2) for individuals who were also
treated with antihypertensive drugs (Table 1, and section F, S1 File).
Subsequently, reductions in blood pressure were translated into reductions of CVD risk
which were applied to the annual risks of stroke and CHD events. For this step, we tested three
different assumptions in scenarios. First, we used the observed blood pressure reduction to
recalculate the Framingham scores for each individual risk profile. Additionally, we applied
two estimates of relative risk reduction that were derived from meta-analyses on the effect of
lowering blood pressure on stroke and CHD outcomes. We compared relative risk reduction
based on a recent meta-analysis by Rapsomaniki et al[48], to the relative risk reduction esti-
mate described by Lawes et al.[7,64] We will refer to these scenarios as “Framingham”, “Rapso-
maniki”, and “Lawes” assumptions (Table 1, and Table B and section F, S1 File).
Mortality and morbidity outcomes were translated into years of life lost (YLLs) due to pre-
mature death and years lived with disability (YLDs), respectively, to calculate the total number
of DALYs in each scenario. To calculate YLDs, we applied disability weights due to CVD events
based on the utilities defined in the GBD 2010 (Table 1, and Table C and section G, S1 File).
[27] We also applied a disability weight to the period of time when patients were on antihyper-
tensive treatment.[27] We used standard methods[65] without age weighting[27] to calculate
DALYs. Incremental cost-effectiveness ratios (ICER) were calculated as the difference in costs
divided by the difference in DALYs between the intervention and reference scenario. We took
a lifetime perspective when calculating costs and health benefits following from events that
occurred in the ten-year intervention timeframe. Future costs and health outcomes were dis-
counted at 3% per year.
2.5 Uncertainty and sensitivity analysis
We constructed 95% confidence intervals around the primary outcome results through a prob-
abilistic sensitivity analysis (PSA; Monte Carlo simulation) in which parameters were ran-
domly sampled from their probability distributions in 1,000 iterations (Table 1). Results from
the PSA are presented in cost-effectiveness acceptability curves.[66] Additionally, one-way sen-
sitivity analyses were conducted in which model parameters were varied outside their confi-
dence intervals. We tested the sensitivity of our model to the proportion of stroke and CHD
events that were fatal within one year; the length of survival of non-fatal events; variation in
above-service delivery costs; the costs of acute care after a stroke event; the costs of acute care
after a CHD event; costs of hypertension care; a change in effect of blood pressure treatment;
increased CVD risk at baseline; and discount rates.
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The model was programmed using Microsoft Excel 2013 (Microsoft Corp), population dis-
tribution and effectiveness data were calculated using Stata (version 12.0; StataCorp). We con-
ducted and present this study following the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) guidelines[67] and the published standards of the Bill and
Melinda Gates Foundation, Methods for Economic Evaluation Project.[68]
Results
3.1 Health impact
Population-level screening and providing anti-hypertensive treatment in the context of a vol-
untary health insurance program using the risk and hypertension based strategy would result
in a 4%, 3%, and 8% reduction in the number of stroke events and a 2%, 3% and 6% reduction
in the number of CHD events using the Framingham, Rapsomaniki, and Lawes assumptions
respectively. In the risk based strategy, a lower number of stroke and CHD events would be
avoided (3% and 2% respectively for the Framingham assumption, 3% and 2% for the Rapso-
maniki assumption and 7% and 4% for the Lawes assumption). The total number of DALYs
averted in a population of 10,000 individuals are presented in Tables 2 and 3 by treatment eligi-
bility strategy.
3.2 Costs
The cost per individual in the reference scenario was US$ 60.8, corresponding to acute event
care and secondary prevention. The cost per individual of the risk and hypertension based
strategy was US$ 99.6 for the Framingham, US$ 99.5 for the Rapsomaniki and US$ 97.4 for the
Lawes scenario. The cost per individual of the risk based strategy was lower compared to the
risk and hypertension based strategy and was estimated at US$ 79.1 for the Framingham, US$
79.0 for the Rapsomaniki and US$ 77.3 for the Lawes scenario (Table 3). The reduction in costs
attributable to a reduction in costs for acute care of CVD events and follow up care due to the
intervention was between 2% and 7%, depending on the scenario (Table 2).
3.3 Cost-effectiveness
The mean ICERs for the risk and hypertension based strategy were US$ 7,815 using the Fra-
mingham assumption, US$ 6,256 using the Rapsomaniki assumption and US$ 1,406 using the
Lawes assumption. The mean ICERs for the risk based strategy were substantially lower at US$
2,959, US$ 2,498 and US$ 732 using the Framingham, Rapsomaniki and Lawes assumptions
respectively (Table 3). The uncertainty bounds around these estimates are presented in
Table 3.
The mean ICER in Lawes for the risk and hypertension based strategy and the mean ICER
in Lawes and Rapsomaniki in the risk based strategy are considered cost-effective at a willing-
ness-to-pay threshold of one GDP per capita per DALY averted, which was US$ 2,742 in Nige-
ria in 2012.[69] However, only one set of assumptions could consistently be considered cost-
effective when we include uncertainty in model parameters (risk based strategy, Lawes).
3.4 Uncertainty analysis
Fig 2A and 2B show the result of the probabilistic sensitivity analysis and illustrate the proba-
bility of antihypertensive treatment provided through the KSHI program to be cost-effective
against a range of willingness-to-pay thresholds. At a willingness-to-pay threshold of US$
2,742 (one GDP per capita), the probability of the risk and hypertension based strategy to be
cost-effective compared to the reference scenario was 1%, 4% and 95% respectively under the
Hypertension Screening and Treatment in Nigeria
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Framingham, Rapsomaniki and Lawes assumptions (Fig 2A). The probability of the program
to be cost-effective when using a risk based strategy was 52%, 68% and 99% respectively under
the Framingham, Rapsomaniki and Lawes assumption (Fig 2B).
The bounds of the 95% confidence intervals included negative ICERs. Negative ICERs in
the case of our model do not indicate a cost-reduction but indicate cases where DALYs are
incurred rather than averted following the burden of being on treatment for long periods of
time without having any events (the strategy is then considered dominated). This occurred in
7% and 3.9% of the 1,000 iterations for the Framingham and the Rapsomaniki scenarios in the
risk and hypertension based strategy and in 0.3% and 0.2% respectively in the risk based strat-
egy. We present the cost-effectiveness plane for all iterations in Fig A, S1 File.
Table 2. Outcomes in costs (US$ 2012) and DALYs averted for a cohort of 10,000 individuals.
Strategy 1. Treatment eligibility: risk and hypertension based Strategy 2. Treatment eligibility: risk based
Reference
scenario
KSHI
Framing-ham
KSHI Rapso-
maniki
KSHI Lawes Reference
scenario
KSHI
Framing-ham
KSHI Rapso-
maniki
KSHI Lawes
Stroke events 241 232 233 221 241 234 235 225
CHD events 416 408 404 392 416 410 407 398
DALYs
averted (from
events
prevented)
reference 130 142 342 reference 95 106 259
DALYs lost
(due to
treatment)
reference 80 80 81 reference 33 33 34
NET DALYs
averted
reference 50 62 261 reference 62 73 226
Total costs 607,608 996,082 995,255 973,734 607,608 790,766 789,974 772,617
Screening
Costs
0 47,400 47,400 47,400 0 47,400 47,400 47,400
Hypertension
treatment
costs
0 293,674 293,893 296,196 0 121,395 121,595 122,775
Above-service
delivery costs
for KSHI
program
0 63,453 63,500 63,998 0 26,229 26,273 26,527
Care after
CVD event
costs
607,608 591,555 590,462 566,141 607,608 595,741 594,707 575,915
Reduction in
acute and
follow-up
costs after
CVD event
reference 2.6% 2.8% 6.8% reference 2.0% 2.1% 5.2%
% of total
costs related
to KSHI
intervention*
0% 36% 36% 36% 0% 25% 25% 27%
*Total costs related to KSHI intervention includes screening, hypertension treatment and above-service delivery costs. Framingham: assuming
recalculation of Framingham equation; Rapsomaniki: assuming relative risk reduction based on Rapsomaniki[48]; Lawes: assuming relative risk reduction
based on Lawes[7] Abbreviations: KSHI: Kwara State Health Insurance; CHD: Coronary Heart Disease; DALYs: Disability Adjusted Life Years; CVD:
Cardiovascular disease.
doi:10.1371/journal.pone.0157925.t002
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One-way sensitivity analyses illustrated that our primary outcome estimates were sensitive
to variations in discount rate, effect of treatment on systolic blood pressure, above-service
delivery costs, inclusion of disability weights for being on antihypertensive treatment and costs
of hypertension treatment (Fig 3A and 3B, and Tables K and L, S1 File. In particular, our esti-
mates based on Framingham and Rapsomaniki assumptions were less robust than those based
on Lawes assumptions to variations in key parameters.
Discussion
Our study found that screening and treatment for hypertension within a health insurance pro-
gram in Nigeria could be cost-effective at a willingness-to-pay threshold of one GDP per capita
per DALY averted. The likelihood of having a cost-effective program was higher when the
hypertensive population eligible for treatment was restricted to those with a high 10-year CVD
risk, than when eligibility was expanded to the population with grade 2 hypertension, irrespec-
tive of 10-year CVD risk.
Our conclusion was sensitive to underlying assumptions and is presented with substantial
uncertainty. Our assumption on CVD risk reductions following treatment of high blood pres-
sure had a large effect on the ICERs. When we applied relative risk reductions as reported by
WHO (Lawes), between 95% (for the risk and hypertension based strategy) and 99% (for the
risk based strategy) of the iterations were considered cost-effective at a willingness-to-pay
threshold of one GDP per capita. When we used a recalculation of the Framingham score after
treatment to determine risk reduction, only 1% and 52% of the iterations were considered cost-
effective respectively.
The reference scenario to which the KSHI scenario is compared represents no access to
hypertension care. This is the best estimate of base case currently in our setting. The KSHI sce-
narios (including two eligibility criteria) present our best representation of the clinical practice
expected in a KSHI setting. In the one-way sensitivity analyses, we vary our input parameters
Table 3. Cost-effectiveness of KSHI program (US$ 2012).
Strategy 1. Treatment eligibility: risk and hypertension based Strategy 2. Treatment eligibility: risk based
Total cost
incurred
Total
DALYs
incurred
DALYs
averted
ICER
compared
to SoC,
mean
ICER
compared
to SoC,
MC,
median
(2.5–97.5
percentile)
Total cost
incurred
Total
DALYs
incurred
DALYs
averted
ICER
compared
to SoC,
mean
ICER
compared
to SoC,
MC,
median
(2.5–97.5
percentile)
Reference
scenario
607,608 5,086 ref ref ref 607,608 5,086 ref ref ref
KSHI
Framing-
ham
996,082 5,036 50 7,815 6,282
(dominated
to 48,193)
790,766 5,024 62 2,959 2,644
(1,270 to
14,379)
KSHI
Rapso-
maniki
995,255 5,024 62 6,256 5,315
(dominated
to 45,211)
789,974 5,013 73 2,498 2,221
(1,121 to
8,484)
KSHI
Lawes
973,734 4,826 260 1,406 1,287
(dominated
to 3,317)
772,617 4,860 226 732 634 (306 to
2,021)
Framingham: assuming recalculation of Framingham equation; Rapsomaniki: assuming relative risk reduction based on Rapsomaniki[48]; Lawes:
assuming relative risk reduction based on Lawes[7] Abbreviations: KSHI: Kwara State Health Insurance; DALYs: Disability Adjusted Life Years; ICER:
incremental cost-effectiveness ratio; SoC: standard of care. MC: monte carlo simulation.
doi:10.1371/journal.pone.0157925.t003
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to extreme ranges in order to assess the robustness of the findings. A reduction in hypertension
care costs increased cost-effectiveness. The estimated reduction in costs was based on a combi-
nation of task-shifting from doctors to nurses, minimal target organ damage screening, and a
reduction in the number of consultations per year.[24] Studies are needed to determine how
and if these changes in service have an effect on health outcomes. An increase in insurance pro-
gram costs decreased the cost-effectiveness of hypertension care. For the base case insurance
program costs, we used a weighted average of realized and projected costs of the first 12 years
of the program. This includes costs of starting up and scaling up of the program that are
expected to decrease over time. We varied this parameter widely to reflect the possibility of this
intervention being set up in another context with much higher program costs. An increase or
Fig 2. 2A: Cost-effectiveness acceptability curve, risk and hypertension based strategy. Fig 2B: Cost-
effectiveness acceptability curve, risk based strategy. Legend Fig 2A and 2B: GDP Nigeria 2012: US$
2,742; Framingham: assuming recalculation of Framingham equation; Rapsomaniki: assuming relative risk
reduction based on Rapsomaniki[48]; Lawes: assuming relative risk reduction based on Lawes[7].
doi:10.1371/journal.pone.0157925.g002
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decrease of systolic blood pressure reduction in response to treatment increased and decreased
the cost-effectiveness respectively. However, our base case reflects the systolic blood pressure
reduction observed in a population living in an area with access to the KSHI program.
Our findings demonstrate limitations of cost-effectiveness analyses for CVD prevention in
SSA. First, there are no long term prospective cohort studies from SSA that have evaluated the
Fig 3. 3A: One-way sensitivity analysis, risk and HT based strategy. Fig 3B: One-way sensitivity analysis, risk based strategy. Legend Fig 3A and
3B: Presents the change in ICER (incremental costs per DALY averted) compared to the baseline when parameter input is either varied in a high and low
bound or when parameter input is varied to an alternative scenario (presented as lower bound). Darker and lighter bars represent the change in ICER when
a parameter is varied to a respectively lower value (or alternative scenario) and higher value compared to the baseline estimate. *effect of treatment on
SBP: -14.6, coverage of 100% for eligible patients and no disability loss for hypertension treatment. ^based on observed costs in a scenario when limited
diagnostic testing and task-shifting from doctors to nurses[24]. Abbreviations: SBP: systolic blood pressure; CHD: coronary heart disease; LVH: left
ventricle hypertrophy. noHT: no hypertension; HT1: hypertension stage 1; HT2: hypertension stage 2. All values for the parameters tested as well as
resulting ICERs are reported in Tables K and L (S1 File).
doi:10.1371/journal.pone.0157925.g003
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association between (change in) CVD risk factors and CVD events and therefore there are no
validated equations to determine 10-year CVD risk or relative risk reductions after treatment
for populations from SSA. Furthermore, the Framingham equation for stroke is not validated
for individuals below 55 years of age and is not intended as a tool to recalculate stroke risk after
treatment. Therefore, our use of the Framingham equations might have underestimated the
baseline risk of our population as evidence suggests that people from SSA have higher inci-
dence of CVD and CVD-related mortality at a younger age and at lower blood pressure levels
compared to people from Caucasian descent.[70–72]
Secondly, the younger age groups with grade 2 hypertension may have a lower 10-year CVD
risk but a high lifetime risk, as has been shown in particular for people from African descent.
[70–72] Clinical guidelines therefore recommend antihypertensive treatment irrespective of
10-year CVD risk in people with grade 2 hypertension.[29,73] For the younger age groups, the
majority of the CVD events is expected to take place after the 10-year time horizon of the inter-
vention. Our model therefore did not capture all the benefits of treatment. At the same time,
the younger age groups did incur a disability weight for using antihypertensive treatment dur-
ing the full time span of the model. This might have led to conservative cost-effectiveness esti-
mates. This also explains why a risk based strategy could be considered more cost-effective, as
less (young) people would be eligible for treatment and therefore will not incur the disability
weight for antihypertensive treatment. Thirdly, like other studies[16–19,21], we limited our
analysis of CVD events to stroke and CHD and did not include other CVD such as heart fail-
ure, vascular renal failure, and peripheral artery disease because equations to estimate the prob-
ability of events or risk reduction after treatment were not available. However, it is known that
especially Africans with hypertension are at increased risk to develop renal and heart failure.
[74–78] Therefore, our estimates of cost-effectiveness are likely to be conservative. Fourthly,
we did not model subsequent events following a primary event. Unfortunately, there is scarce
data from SSA on the probability and costs of re-events, or on disability and survival after sub-
sequent events following a primary event to inform our model. Therefore, we take into account
re-events by using average survival time after an event. This average survival includes life years
lost due to re-events as well as follow-up care costs by means of secondary prevention of CVD
events. Fifthly, by comparing each scenario to the base case separately, we are providing a lim-
ited scope of the effects that might be achieved with each intervention. While this scoping exer-
cise is valuable given the paucity of CVD-related economic evaluations in SSA, ideally, we
would compare mutually exclusive scenarios simultaneously to identify the optimal expansion
pathway given a cost-effectiveness threshold. Finally, we did not estimate the effect of scale on
unit costs, for lack of evidence of economies or diseconomies of scale in this population and
restricted the analysis to a healthcare provider perspective. As CVD in an African population
typically occurs during the productive age[70], a societal perspective taking productivity losses
due to CVD into account would probably have resulted in more cost-effective estimates of pre-
ventive treatment.
Previous studies evaluating cost-effectiveness of CVD prevention or hypertension care in
SSA reported lower ICERs compared to our results.[16–19,21] However, most studies make
assumptions on costs and treatment effects based on international databases and studies from
high income countries.[16,18,19,21] In general, they use lower estimates for costs of preventive
treatment, do not include disability weights for being on antihypertensive treatment (exclusion
of this disability weight in a one-way analysis showed an improvement in cost-effectiveness),
and use relative risk reductions based on the Lawes study [7] that reports larger effects of treat-
ment compared to other studies.[48] The strength of our study is, therefore, the use of empiri-
cally collected data for population risk distributions, costs of care, treatment coverage, blood
pressure reduction after treatment, and the use of several sources for CVD risk reduction after
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treatment to illustrate the uncertainty around these estimates. In line with the recommenda-
tions from the global burden of disease study [27], we included a 0.031 disability weight for
using antihypertensive treatment as the use of chronic preventive treatment has been shown to
reduce the quality of life.[79] This is especially relevant in settings with long travel and waiting
times for healthcare such as in SSA.
Recent discussions about willingness-to-pay thresholds have raised the concern that any
chosen threshold (such as one or three GDP per capita) is of limited value for decision making
as interventions can be cost-effective but not affordable or feasible to implement.[80] This is
particularly relevant in our study, as GDP per capita is a national measure, while we aim to
inform decision making in one of Nigeria’s poorest states.
In settings such as in Nigeria, where almost 66% of healthcare expenditures is paid out-of-
pocket by patients[11], coverage of CVD prevention treatment will remain low if access to
care for patients is not guaranteed. Although CVD preventive treatment may be considered
cost-effective, implementation is hampered by lack of affordability due to low healthcare
budgets in many SSA countries. [10,11] For example, total public healthcare expenditure per
capita was only US$ 93 in Nigeria in 2012.[81] We evaluated cost-effectiveness of hyperten-
sion care within a health insurance program for low income groups. The co-premium for
enrollees of the health insurance program of US$ 3 is low and represents 1% of the annual
per capita consumption in the lowest consumption quintile of the population in which the
KSHI program is available. However, for some of the poorest households even this small co-
premium is still not affordable. To ensure equity and accessibility, the Kwara State Govern-
ment, which subsidizes the remainder of the premium, has the intention to exempt the poor-
est vulnerable groups from co-premiums in the future. In addition, other states in Nigeria are
aiming for universal coverage in the future. By embedding hypertension care in an opera-
tional program and including above-service delivery costs in our analysis, our cost-effective-
ness estimates move away from a theoretical analysis and reflect the potential results of a real
world intervention that has been proven feasible in providing patients with access to care.
Policymakers can compare our results to the cost-effectiveness of CVD prevention care deliv-
ery through other programs, thereby making informed choices about the best strategy to
combat the increasing burden of CVD.
Conclusions
Hypertension screening and treatment may be cost-effective in rural Nigeria, at a willingness-
to-pay threshold of one GDP per capita per DALY averted, with an important uncertainty
around this conclusion. Even if cost-effective, CVD prevention may not be affordable in many
SSA settings within current levels of government healthcare expenditures. Public-private part-
nerships such as the KSHI program provide opportunities to finance CVD prevention care in
SSA.
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